Hexacath's Titan2 Stent Studied to Treat Small Coronary Arteries

July 22, 2010—In Catheterization and Cardiovascular Interventions, Raúl Valdesuso, MD, et al published findings from the EXTREME registry, a study that sought to explore the immediate results of Titan2 stent (Hexacath, Rueil-Malmaison, France) implantation in small coronary arteries, as well as the incidence of major adverse cardiac events (MACE) at 6-month follow-up (2010:76:281–287).

According to the investigators, the safety of the Titan2 titanium-nitride-oxide–coated stent has been confirmed in several studies in real-life unselected populations. In this study, the investigators enrolled 311 consecutive patients who were admitted for percutaneous intervention for at least one significant (50%) de novo lesion in a native small coronary artery (2–2.75 mm). All lesions were treated with Titan2 stent implantation. Patients were prospectively followed up for at least 6 months. The primary endpoint was MACE at 6-month follow-up (death, myocardial infarction, or target vessel revascularization). Secondary endpoints included angiographic and clinical procedural success, in-hospital MACE, target lesion revascularization during follow-up, and stent thrombosis.

The investigators reported that the mean patient age was 67.3 ± 10.9 years (65.9% men). A total of 356 Titan2 stents were implanted in 353 lesions. Angiographic and clinical procedural success was achieved in 344 (97.5%) patients. No case of in-hospital MACE or acute stent thrombosis was reported. Clinical follow-up was completed for an average of 8 ± 2 months. Two patients (0.7%) died, and six (2.1%) developed myocardial infarction. Target lesion revascularization was performed in 12 patients (4.2%) and target vessel revascularization in 16 patients (5.5%); all were clinically driven. Cumulative MACE occurred in 20 patients (6.9%). One patient experienced subacute stent thrombosis but no late stent thrombosis.

From these data, the investigators concluded that Titan2 stent implantation in small coronary arteries achieves excellent immediate outcome with a low incidence of MACE at midterm follow-up.